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Abstract
Aims The aims of the study were to evaluate head and
neck cancer (HNC) patient’s compliance to the planned
radiation therapy (RT) using the department policy estab-
lished in 2005 at IPOCFG and to estimate the impact on
treatment outcome due to failure in receiving RT as
prescribed.
Materials and methods 359 HNC patients irradiated from
2007 to 2013 were included in this study. Patient cohort
was divided into Group 1: patients receiving RT as pre-
scribed and Group 2: patients that interrupted or suspended
RT. Group Tox is the subgroup of patients that interrupted
RT due to toxicity or intercurrent disease. Number and
causes for treatment interruptions were assessed. The
cumulative incidence of locoregional control (LRC), dis-
ease-free survival (DFS) and overall survival for Groups 1
and 2 was determined. Cox regression was performed to
investigate potential hazard factors and logistic regression
was made to determine risk factors related to treatment
interruptions.
Results Major causes for treatment interruptions were
toxicity plus intercurrent disease (41.7 %) and public hol-
idays (30.1 %). 10.3 % of the patients interrupted
3–9 days. Significant differences in survival distributions
of the LRC between Groups 1 and 2, of up to 19 %, were
found in the subgroup of patients with N2–3 tumours, for
post-operative RT and for concomitant RT. Treatment
breaks larger than two days had an almost fourfold
increased risk of poorer LRC and DFS.
Conclusions Twin accelerators and treating on public
holidays are effective measures minimizing RT breaks. For
HNC, patient compliance is mostly limited by RT side-
effects. Efforts to maintain RT biological effective dose in
HNC must be always undertaken.
Keywords Head and neck cancer  Radiation therapy 
Treatment interruptions  Clinical outcome  IMRT
Introduction
The influence of overall treatment time on outcome in RT
of head and neck (HN) cancer is fairly well documented
[1–3]. Treatment interruptions of 1 week resulted in losses
in locoregional control of about 10 % [1, 4]. Strategies to
keep treatment effectiveness in the face of planned or
unplanned interruptions have, therefore, been suggested [3,
5]. Transferring patients to a similar linac to overcome
machine breaks or the delivery of two fractions per day,
separated by at least a 6–8 h interval for sublethal damage
to repair, are approaches to accomplish the prescribed
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overall treatment time. Alternatively, increasing the dose
per fraction or the number of fractions are the strategies
that have to be balanced against the risks of increased
toxicity. To maintain biological treatment effectiveness in
HN tumours, an extra dose of about 0.6–0.75 Gy per day of
protraction would be required to counteract the effects of
accelerated tumour repopulation [6].
At the Portuguese Institute of Oncology of Coimbra
Francisco Gentil (IPOCFG), the causes for treatment
interruptions for all patients treated in one treatment unit
were assessed in 2005 [7]. Public holidays were the major
cause for interruptions and most patients interrupted less
than 5 days. Such study led to a change in department
policy. First, patients were categorized by radiation
oncologists. For those patients in whom breaks were likely
to affect the outcome, treatments were delivered every day
of the week despite holidays (except for Christmas and
New Year’s Day). Secondly, twin accelerators were
acquired allowing the transfer of patients in case of mal-
function or maintenance. For planned interruptions, if
possible, overall treatment time is kept by treating on the
weekend or by delivering two fractions per day from the
same plan or from the boost plan. The cause for treatment
interruption is then documented in the patient chart.
The first aim of this study was to assess compliance to
the planned RT for HN cancer patients using the clinical
protocol adopted since 2005 at IPOCFG [7]. Secondly, the
aim of the study was to evaluate treatment outcome for this
pathology, irradiated mostly with Intensity Modulated
Radiation Therapy (IMRT), for patients that received RT as
planned and, finally, to estimate the impact on treatment




From May 2007 to July 2013, 359 patients with HN
squamous cell carcinoma (90.0 %) or undifferentiated
carcinoma were treated at IPOCFG mostly with IMRT
(86 %). Palliative and re-irradiated cases were not included
in this cohort. All clinical patient data were collected by the
radiation oncologists of the institute during the RT medical
appointments. Thus, in this retrospective study, informed
consent was not required. In this study, patient cohort was
divided into two groups: Group 1 patients that received RT
as prescribed (patients treated with multiple fractions per
day or concomitant boost due to public holidays were
included in this group, 12 cases); and Group 2 patients that
failed to receive RT as planned, and were thus irradiated
with a biological effective dose lower than prescribed, due
to RT treatment breaks or incomplete treatment (69 and 11
cases, respectively). Ten patients that interrupted RT but
received dose compensation were excluded from the sur-
vival analysis but were accounted for in the assessment of
the causes for treatment interruptions. Mean follow-up time
for Group 1 was 19.3 months [95 % confidence intervals
(CI) 17.7–20.9 months] and for Group 2 was 22.5 months
(95 % CI 19.2–25.6 months). A subgroup of patients in the
total cohort that interrupted RT due to toxicity or inter-
current disease (i.e. unrelated comorbidity) was created to
evaluate the impact of these factors on treatment inter-
ruptions (Group Tox). This was composed of a total of 42
patients that interrupted treatment due to severe mucositis,
radiodermitis, haematological toxicity, infection (e.g.
pneumonia), anxiety, nausea/vomiting and mask intoler-
ance. Patients and disease characteristics for all patients
groups are summarized in Table 1.
Details on RT are described in detail elsewhere [8]. In
summary, target volume delineation followed Gregoire
et al.’s guidelines [9, 10]. Prescription doses to primary
tumour volume (post-operative or definitive) and large
adenopathies ranged from 59.4 to 70.2 Gy and to high- and
low-risk lymph nodes ranged from 50.4 to 59.4 Gy. Con-
current chemotherapy was mainly cisplatin based. Patients
unable to undergo this scheme were evaluated to cetux-
imab. Planning was performed in the Oncentra Treatment
Planning System (Elekta/Nucletron). Simpler target vol-
umes were irradiated with 3D conformal treatment tech-
niques. More complex cases were irradiated with IMRT.
Forwardly, optimized IMRT using a fractionation schedule
of five fractions of 1.8 Gy per week was used from 2006
and progressively replaced since 2008 by inversely opti-
mized IMRT (step-and-shoot Oncor Avant-Garde from
Siemens) where dose integration of at least two prescrip-
tion dose levels was used provided that a dose per fraction
larger than 2.2 Gy was not obtained [11]. Dose assessment
was based on collapsed-cone dose-computation algorithm
for all patients.
Statistical analysis
Number and causes for treatment interruptions for this
patient cohort were assessed. Multivariate logistic binary
regressions were used to investigate factors that may be
associated with interruption of RT due to toxicity or
intercurrent disease. Adjusted odds ratios (adj. OR) and
95 % CI were calculated for the factors: age, tumour site
(hypopharynx ? pharyngeal-laryngeal ? larynx vs oral
cavity vs oropharynx vs nasopharynx), stage T(1–2 vs 2–3)
and N(0–1 vs 2–3), type of RT (concomitant vs non-con-
comitant) and type of treatment (post-operative vs
definitive).
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Locoregional control was defined from the time com-
plete tumour response to the initial treatment protocol was
obtained up to the time of recurrence. Complete tumour
response was achieved in 80.2 % of the patients. Disease-
free survival was defined from the time since complete
tumour response to the therapy has been achieved up to the
time of recurrence, metastasis, second tumour or death,
independently of appearance order. The rate of distant
metastasis and the rate of overall survival were calculated
from the start of RT. The cumulative incidence of locore-
gional control, disease-free survival, distant metastasis and
overall survival were calculated using the Kaplan–Meier
method for the total population cohort and stratifying the
variables (one at a time): age, gender, T stage and N stage,
type of treatment (post-operative vs definitive) and type of
RT (concomitant vs non-concomitant). Log-rank test was
used to test the equality of the survival distributions
between Groups 1 and 2.
Potential prognostic factors [hazard ratios (HR) and the
correspondent 95 % CI] with association with locoregional
control, disease-free survival and overall survival were
explored in univariate and multivariate analysis performed
using Cox regression models. These were: age (continuous
variable), gender, tumour site (hypopharynx ? pharyn-
geal-laryngeal ? larynx vs oropharynx vs oral cavity), T
stage (1–2 vs 3–4) and N stage (0–1 vs 2–3), type of RT
Table 1 Patient and treatment
characteristics
Characteristics Total, N (%) Group 1, N (%) Group 2, N (%) Group Tox, N (%)
Age
B55 150 (42.0) 104 (38.7) 41 (51.3) 20 (47.6)
[55 209 (58.2) 165 (61.3) 39 (48.8) 22 (52.4)
Gender
Male 304 (84.7) 236 (87.7) 61 (76.3) 29 (69.0)
Female 55 (15.3) 33 (12.3) 19 (23.8) 13 (31.0)
Site
Larynx 85 (23.7) 67 (24.9) 18 (22.5) 7 (16.7)
Oral cavity 71 (19.8) 58 (21.6) 12 (15.0) 8 (19.0)
Oropharynx 70 (19.5) 49 (18.2) 17 (21.3) 12 (28.6)
Nasopharynx 45 (12.5) 31 (11.5) 11 (13.8) 10 (23.8)
Pharyngeal-laryngeal 39 (10.9) 28 (10.4) 10 (12.5) 1 (2.4)
Hypopharynx 27 (7.5) 18 (6.7) 8 (10.0) 3 (7.1)
Others 22 (6.1) 18 (6.7) 4 (5.0) 1 (2.4)
T stage
1–2 187 (52.1) 151 (56.1) 32 (40.0) 15 (35.7)
3–4 172 (47.9) 118 (43.9) 48 (60.0) 27 (64.3)
N stage
0–1 158 (44.0) 133 (49.4) 23 (28.8) 10 (23.8)
2–3 201 (56.0) 136 (50.6) 57 (71.3) 32 (76.2)
Type treatment
Post-operative 145 (40.4) 119 (44.2) 24 (30.0) 10 (23.8)
Definitive 214 (59.6) 150 (55.7) 56 (70.0) 32 (76.2)
Type of RT
Non-concomitant 191 (53.2) 157 (58.4) 31 (38.7) 12 (28.6)
Concomitant 168 (46.8) 112 (41.6) 49 (61.3) 30 (71.4)
RT technique
3DCRT 52 (14.5) 46 (17.1) 6 (7.5) 1 (2.4)
fIMRT 98 (27.3) 77 (28.6) 20 (25.0) 6 (14.3)
IMRT 209 (58.2) 146 (54.3) 54 (67.5) 35 (83.4)
Group 1 is the group of patients that received RT in the planned overall treatment time, Group 2 are the
patients with extended treatment time or suspended RT and Group Tox is the group of patients, from the
total cohort, that interrupted RT due to toxicity or intercurrent disease. 10 patients that received extra
fractions to compensate for RT interruptions were not included in Group 1 or 2, but were accounted for in
the total
3DCRT 3D Conformal RT, fIMRT forward optimized IMRT and IMRT refers to inversely optimized
Intensity Modulated RT
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(concomitant vs non-concomitant), type of treatment (post-
operative vs definitive), prescribed dose (*59 vs *65 vs
*70/Gy), dose per fraction (B2 vs [2 Gy), overall treat-
ment time (continuous variable) and duration of the gap (0
vs 1–2 days vs [2 days). Due to the high correlation
between input variables, overall treatment time and pre-
scribed dose were excluded from the analysis.
All statistical analyses were performed using SPSS
Software, version 20.0 (SPSS, Inc., Chicago, IL, USA) and
p values under 0.05 were considered significant.
Results
The major cause for unplanned treatment interruptions was
RT toxicity plus intercurrent disease (41.7 %). Replanning,
due to patient weight loss, was the cause for the treatment
interruption in six patients (5.8 %) by a maximum of
2 days. Public holiday (Christmas and New Year) was the
major cause for planned treatment interruptions (30.1 %).
Machine maintenance or breakdown was the cause for the
interruption in only five patients (4.9 %) (Supplementary
material, Table 1).
Median overall treatment time for Group 1 was
44.0 ± 3.7 days (range 37–54 days) and for Group 2 was
47.0 ± 4.9 days (range 35–61 days). Median overall
treatment time for patients with extended delivery time was
47.0 ± 4.4 days (range 39–61 days) and for patients with
incomplete treatment was 42.0 ± 4.6 days (range
35–49 days).
In Table 2, the percentage of treatment interruptions by
the duration of the gap is shown for all patients. Almost
75 % of all patients received RT in the planned schedule or
in less time (9 cases). The shorter overall treatment time
was due to the delivery of multiple fractions per day or
concomitant boost to compensate for planned treatment
interruptions. The maximum number of days of interrup-
tion was 9 days. From the patients that interrupted, 11.7 %
interrupted 1 or 2 days, 7.5 % interrupted 3–5 days and
2.8 % (10 cases) interrupted more than 5 days. 3.1 % of
the patients did not complete RT due to severe RT toxicity
and intercurrent disease.
More than 80 % of the patients with earlier stages of the
disease received their treatment as planned compared to
around 68 % of the patients with more advanced tumour
stages (Table 2). The percentage of patients that inter-
rupted more than 3 days with T1–2 and T3–4 tumours was
7.0 and 14 %, respectively. Risk factors significantly
associated with treatment interruption due to RT toxicity or
Table 2 Percentage of
treatment breaks by duration of
gap and results of the
multivariate logistic regression
for treatment interruptions due
to RT toxicity or intercurrent
disease (interc dis)
Duration of gap/days N/% Toxicity ? interc dis
0 1–2 3–5 5–9 Inc. RT Adj. OR 95 % CI p
Total 74.9 11.7 7.5 2.8 3.1
Tumour site
Hypop ? PhL ? Larynx 74.8 9.3 9.3 2.0 3.3 1 – –
Oral cavity 81.7 7.0 4.2 2.8 4.2 2.09 [0.74; 5.91] 0.165
Oropharynx 70.0 17.1 4.3 4.3 4.3 2.76 [1.07; 7.10] 0.035
Nasopharynx 62.2 17.8 15.6 4.4 0.0 2.59 [0.91; 7.36] 0.075
T stage
1–2 80.2 10.2 5.9 1.1 2.7 1 – –
3–4 69.2 13.4 9.3 4.7 3.5 2.86 [1.29; 6.33] 0.009
N stage
0–1 84.2 8.2 5.1 1.9 0.6 1 – –
2–3 67.7 14.4 9.5 3.5 5.0 2.07 [0.87; 4.96] 0.102
Type RT
No-concomitant 82.2 9.4 5.8 0.5 2.1 1 – –
Concomitant 66.7 14.3 9.5 5.4 4.2 1.96 [0.83; 4.60] 0.124
Type treatment
Post-operative 82.8 5.5 4.8 2.8 4.1 1 – –
Definitive 69.6 15.9 9.3 2.8 2.3 1.42 [0.55; 3.67] 0.473
Results for: age (toxicity ? intercurrent disease) adj. OR = 1.00, 95 % CI [0.97; 1.03], p = 0.811
Inc. RT shows the percentage of patients that suspended RT. Concomitant refers to patients that received
cisplatin or cetuximab concomitantly with RT while non-concomitant refers to other cases
Bold values are statistically significant
Adj. OR adjusted odd ratio and 95 % CI for its 95 % confidence intervals, Hypop ? PhL hypoharynx and
pharyngeal-laryngeal tumours
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intercurrent disease were T stage and oropharynx tumours
(Table 2).
At 24 months, locoregional control for Group 1 and for
Group 2 was 87.0 and 76.7 %, disease-free survival was
71.2 and 60.0 %, distant metastases rate was 24.6 and
27.4 % and overall survival was 73.0 and 62.9 %, respec-
tively. Although Group 1 when compared with Group 2
always presented better results in all studied endpoints,
differences in the probability distribution were not statis-
tically significant.
Significant differences in the Kaplan–Meier survival
curves for the probability of locoregional control between
Groups 1 and 2 were obtained for the subgroups: stage N3-4,
concomitant RT and for post-operative RT (Fig. 1). At
24 months, locoregional for Group 1 vs Group 2 for patients
with N2–3 tumours was 86.9 vs 69.4 %, for concomitant RT
was 91.8 vs 77.7 % and for post-operative RT was 90.2 vs
71.5 %, respectively. Differences in the probability of
locoregional control between Groups 1 and 2 were also
obtained for the subgroups stage T1–2 and T2–3 but without
reaching statistical significance. Similarly, no statistical
significant differences were obtained for the endpoints dis-
ease-free survival or overall survival for all evaluated sub-
groups (Supplementary material—Table 2).
In Table 3, the variables significantly associated with the
probability of locoregional control, disease-free survival and
overall survival in univariate and multivariate analysis are
shown. Duration of the gap superior to 2 days was signifi-
cantly related to an increased risk of tumour recurrence and
poorer disease-free survival both in univariate analysis and
multivariate analysis (HR for LRC and DFS *3). T stage
was significantly associated with an increased risk of death
both in univariate and multivariate analysis (HR 1.84) while
N stage was significantly related to worse disease-free sur-
vival and overall survival (HR*2). Inoperable tumour cases
undergoing definitive RT, compared to post-operative RT,
were significantly related with worst locoregional control
(HR 3.25) and disease-free survival (HR 2.49).
Discussion
The fast repopulation rate of HN tumours cells occurring
during RT makes overall treatment time one of the most
important factors affecting the probability of tumour con-
trol [1–3, 6, 12]. To improve patient compliance to the
prescribed treatment time, new strategies were adopted at
IPOCFG [7]. With these policies, almost 75 % of the HN
cancer patients in this cohort received their treatment as
planned (Table 2). Excluding the patients who interrupted
RT due to complications, therapy for these patients was
delivered as prescribed to almost 88 % of the patients.
The most important factors that minimized the rate of
the department-related RT interruptions were: first, twin
linear accelerators allowed the safe delivery of the planned
treatments and second, the delivery of RT 5 days a week in
priority patients (with the exception of Christmas and New
Year’s days). The number of interruptions due to machine
maintenance and breakdown was reduced from 43 %
before 2005 to 4.9 %. Some minor organization issues are
always needed to reschedule non-priority patients. How-
ever, transfer of priority patients between dosimetrically
identical machines completely eliminated all workload
related with replanning for a different machine. With the
conversion of almost all public holidays into working days,
a reduction of interruptions due to holidays from 49 to
30 % was possible. In half of the cases, interruptions were
compensated by the delivery of multiple fractions per day,
concomitant boost, treatments on the weekend or an
increase in the number of fractions delivered. Even so,
overall treatment time for patients that interrupted their
treatment due to public holidays was in average 3 days
Fig. 1 Cumulative incidence of: locoregional control for patients that complied with idealized overall treatment time (Group 1) and patients with
extended treatment time or incomplete treatment (Group 2) for the subgroups: stage N2–3, concomitant RT and post-operative RT, respectively
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longer than prescribed. Further measures to avoid loss in
treatment outcome as a result of the extension in overall
treatment time due to Christmas holidays may thus still be
needed.
Domestic reasons and replanning had a smaller impact
on the number of treatment interruptions than department-
related causes. In most cases, personal motives for missing
the treatment were not documented. Strike on public
transports, holidays and private celebrations were some of
the reasons reported by patients for non-compliance. With
the availability of tools for adaptive RT, an increasing
number of cases may benefit from replanning. In this
cohort, in 86 % of the cases in which adaptive RT was
applied, treatment was resumed without interruption. In
case treatment interruption was unavoidable, the duration
of the gap did not exceed 2 days. If the therapeutic
advantages of adaptive RT [13] outweigh the losses from
an extended overall treatment time still needs to be deter-
mined. Better patient and staff education and closer patient
follow-up may contribute to reduce, or ideally eliminate,
the number of treatment breaks due to domestic reasons
and adaptive RT.
Patients with inoperable advanced HN tumours are
generally advised for concomitant definitive RT. Larger RT
Table 3 Results from Cox
regression analysis for the
endpoints locoregional control,
disease-free survival and overall
survival
Univariate analysis Multivariate analysis
HR 95 % CI p HR 95 % CI p
Locoregional control
Type treatment
Post-operative 1 – – 1 – –
Definitive 1.75 [0.79; 3.88] 0.172 3.25 [1.12; 9.48] 0.030
Duration of gap
0 1 – – 1 – –
1–2 days 2.16 [0.80; 5.88] 0.130 1.82 [0.65; 5.09] 0.251
[2 days 2.99 [1.01; 8.92] 0.049 3.98 [1.12; 14.15] 0.033
Disease-free survival
N stage
0–1 1 – – 1 – –
2–3 1.95 [1.14;3.32] 0.014 2.03 [1.09; 3.80] 0.026
Type treatment
Post-operative 1 – – 1 – –
Definitive 1.92 [1.13;3.27] 0.016 2.49 [1.24; 5.00] 0.010
Duration of gap
0 1 – – 1 – –
1–2 days 1.33 [0.62;2.82] 0.464 1.17 [0.54; 2.53] 0.695
[2 days 2.53 [1.19;5.38] 0.016 3.05 [1.31; 6.97] 0.009
Overall survival
T stage
1–2 1 – – 1 – –
3–4 2.33 [1.33; 4.08] 0.003 1.84 [1.02; 3.34] 0.042
N stage
0–1 1 – – 1 – –
2–3 2.62 [1.45; 4.76] 0.002 2.20 [1.15;4.21] 0.018
Type treatment
Post-operative 1 – – 1 – –
Definitive 1.56 [0.93;2.62] 0.090 1.43 [0.71; 2.88] 0.312
Duration of gap
0 1 – – 1 – –
1–2 days 1.42 [0.69; 2.90] 0.342 1.11 [0.53; 2.33] 0.791
[2 days 1.86 [0.91; 3.80] 0.092 1.53 [0.72; 3.25] 0.272
Other variables considered (p[ 0.10): age, gender, tumour site, dose per fraction, type of RT
Bold values are statistically significant
HR hazard ratio and 95 % CI for its 95 % confidence intervals
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doses imply a longer overall treatment time raising the
odds for treatment interruptions due to department-related
causes. Patients with more advanced tumour stages
undergoing definitive RT were less likely to receive treat-
ment in the idealized time (Table 2). Also, the duration of
the treatment break was longer for such patients. More
aggressive treatments delivered with definitive concomi-
tant RT, mostly, with cisplatin are generally associated
with increased patient toxicity. Compliance to the planned
RT may then become more difficult. However, despite the
increased risk for treatment interruptions due to toxicity or
intercurrent disease for advanced HN tumour cases treated
with definitive RT and concomitant RT, these were not
statistically associated with interruption of RT due to co-
morbidity (Table 2—right column). Only advanced T stage
and oropharynx tumour cases remained significantly rela-
ted to RT interruption due to RT toxicity plus intercurrent
disease.
The new department policies significantly raised the
number of patients receiving RT as planned compared to
the compliance obtained before 2005. Even so, comparing
survival estimates for patients receiving RT as prescribed
against patients that failed in receiving the planned treat-
ment, differences up to 10 % in locoregional control, dis-
ease-free survival and overall survival between the two
groups were obtained. None of these differences were
statistically significant and, therefore, a longer follow-up is
needed to strengthen the findings of this study limited by
the small number of events in each group and its retro-
spective nature.
By stratifying the population into subcategories, statisti-
cally significant differences in the probability of locore-
gional control between Groups 1 and 2 for patients with
advanced N stage tumours, patients receiving post-operative
RT and for the subgroup undergoing concomitant
chemoradiation were obtained (Fig. 1). The difference in
mean overall treatment time between Groups 1 and 2 for each
subcategory ranged from 2 to 3 days, resulting in differences
in the probability of locoregional control at 2 years of
14–19 %. Shaverdian et al. [14] reported that for cervical
cancer extended overall treatment time had no impact on
patients receiving concomitant chemoradiation. However,
Cannon et al. [15] showed that this was not the case for head
and neck tumours. In this study, the therapeutic benefits
obtained with multimodality treatments, through surgery or
concomitant chemotherapy combined with RT, were lost
when RT was not delivered uninterruptedly (Supplementary
material—Table 2). Efforts to deliver RT as planned to HN
cancer patients should, therefore, be always undertaken to
maximize treatment success.
Suwinski et al. [1] reported that a protraction in RT of
post-operative head and neck tumour patients of 10 days
resulted in a 10–20 % difference in recurrence-free
survival. Interestingly, these differences were obtained for
treatments longer than 45 days and for gap durations
longer than 5 days. In this study, no patient interrupted
more than 9 days and the number of patients with a gap
larger than 2 days was reduced from about 46 % [7] to
10.3 % using the new department policies. For the survival
endpoints investigated, the hazard risk of treatment failure
increased with the duration of the RT break (Table 3). An
interruption longer than just 2 days was significantly
associated with poorer locoregional control and disease-
free survival increasing the risk of treatment failure by a
factor of three to four. RT gaps larger than 2 days should,
therefore, be strongly avoided. Actions to keep overall
treatment time and the biological effective dose in HN
tumour cases should always be adopted if treatment inter-
ruptions are unavoidable.
Conclusion
The purchase of twin accelerators and treating on public
holidays has succeeded to significantly reduce department-
related RT interruptions. For RT of HN tumour cases,
compliance to the planned treatment is mostly limited by the
severity of acute side-effects. Preventing measures to mini-
mize mucositis, dysphagia and pain during RT should,
therefore, be adopted especially in patients treated with
advanced tumours (especially oropharynx tumours cases). In
the face of inevitable treatment interruptions, the duration of
the gap should be minimized and kept under 2 days. A pro-
traction in overall treatment time by more than 2 days
increased the relative risk of treatment failure by three to four
times compared to the delivery of RT without interruptions.
Strategies to keep prescribed biological effectiveness in RT
of HN tumours should, therefore, be always adopted.
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5. Garau M, Monné J, Serés MJ. Monfà Binefa C, Peraire Llopis M. Compliance
to the prescribed overall treatment time (OTT) of curative radiotherapy in
normal clinical practice and impact on treatment duration of counteracting short
interruptions by treating patients on Saturdays. Clin Transl Oncol.
2009;11(5):302–11.
6. Tarnawski R, Fowler J, Skladowski K, Swierniak A, Suwinski R, Maciejewski
B, et al. How fast is repopulation of tumor cells during the treatment gap? Int J
Radiat Oncol Biol Phys. 2002;54(1):229–36.
7. Andrade L, Pais M. Lopes MC unsheduled interruptions and prolongation of
treatment time in radiotherapy—one year study. Radiother Oncol.
2005;76(Supp. 2):S79.
8. Ferreira BC, Marques RV, Khouri L, Santos T, Sá-Couto P, Lopes MC.
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9. Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, et al. CT-
based delineation of lymph node levels and related CTVs in the node-negative
neck: DAHANCA, EORTC, GORTEC, NCIC. RTOG consensus guidelines.
Radiother Oncol. 2003;69(3):227–36.
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